LCM
INDV icon

Legato Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Legato Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$616K Buy
20,214
+7,170
+55% +$237K 0.06% 482
2025
Q4 		$468K Buy
+13,044
New +$398K 0.04% 571

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Legato Capital Management's INDV Position: Q1 2026 in Review

Legato Capital Management increased its Indivior Pharmaceuticals (INDV) stake by 55% in Q1 2026, buying an estimated $237K and bringing the position to 20,214 shares worth $616K. The position accounts for 0.06% of the portfolio, ranked #482.

Legato Capital Management first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Legato Capital Management held 20,214 shares of Indivior Pharmaceuticals worth $616K as of Q1 2026.
  • Legato Capital Management bought 7,170 Indivior Pharmaceuticals shares in Q1 2026, an estimated $237K.
  • Indivior Pharmaceuticals made up 0.06% of Legato Capital Management's portfolio in Q1 2026, its #482 holding.
  • Legato Capital Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.